Ribociclib latest price in 2025

Ribociclib/Calilon (Ribociclib) is a highly representative CDK4/6 inhibitor in the field of breast cancer. Its main application is the treatment of patients with hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer. Compared with endocrine therapy alone, the combination regimen of ribociclib significantly improves clinical efficacy, making it quickly become one of the core drugs recommended by international treatment guidelines. In terms of applications, reboxiclib is often used in combination with aromatase inhibitors (such as letrozole) or fulvestrant to inhibit the cycle progression of cancer cells and delay disease progression. Its therapeutic advantages lie in the durability of disease control and the potential to improve patients' quality of life.

In the Chinese market, the original drug Riboxil has been officially launched and has been included in the national medical insurance reimbursement catalog, greatly improving patient accessibility. The common specification in China is 200mg*63 tablets, and the price per box is about more than 4,000 yuan. After medical insurance payment, the patient's out-of-pocket payment ratio has dropped significantly, which is significantly reduced compared to the high drug cost when it was first launched. As medical insurance negotiations continue to advance, the use rate of Riboxil in China continues to increase, which also means that more breast cancer patients can receive cutting-edge targeted therapy within an affordable range.

In the international market, Riboxil has already been approved by the U.S.FDA and European EMA, and is sold in many countries. Common specifications in Europe include 200mg 21 tablets, 200mg 42 tablets and 200mg 63 tablets. Each box may be sold for more than 20,000 yuan, and the price level is significantly higher than the domestic market. In India, because the original research company has a production base, the price of 200mg63 tablets is often more than 3,000 yuan, which may change due to exchange rate fluctuations. In addition, generic versions of Riboxil have appeared in overseas markets, such as 200mg*21 tablets produced by a Laos pharmaceutical factory, which may be sold for more than 1,000 yuan per box. Although generic drugs are relatively cheap, their marketing status, compliance and channel stability in different countries still need to be strictly screened.

Reference materials:https://us.kisqali.com/